SUPPLEMENT: Algorithm for Pre-/Post-Procedure Measures for Facial Laser and Energy Devices Treatment

January 2021 | Volume 20 | Issue 1 | Department | ss3 | Copyright © January 2021


Published online December 24, 2020

Michael Gold MD FAAD,a Anneke Andriessen PhD,b David J. Goldberg MD JD FAAD,c Komel V. Grover MBA,d Shasa Hu MD FAAD,e Z. Paul Lorenc MD FACS,f Stephen H. Mandy MD FAAD,g Janelle M.Vega MD FAADh

aGold Skin Care Center, Nashville,TN;Vanderbilt University School of Medicine and Nursing, Nashville,TN
bRadboud UMC Nijmegen,Andriessen Consultants, Malden, Netherlands
cSkin Laser & Surgery Specialists of NY and NJ, Hackensack, NJ; Icahn School of Medicine at Mt. Sinai, New York, NY
dStrategic Development, Swiss American CDMO, Dallas,TX
eDr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL
fLorenc Aesthetic Plastic Surgery Center, New York, NY; Department of Plastic Surgery, Lenox Hill Hospital, New York, NY
gDr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami FL
hMayoral Dermatology, Miami, FL
cDallas Center for Dermatology and Aesthetics, Dallas,TX
dGeorge Washington University,Washington, DC

respondents, most physicians started the antiviral one day before the procedure (thirty-two [58.2%]), fifteen (27.3%) started the same day, one physician (1.8%) started the antiviral one day after the procedure, and seven (12.7%) answered "other".6 The antiviral was typically used for five days (twenty-five [50.0%]) or seven days (seventeen [34.0%]).6

The panel recommends the use of oral antiviral prophylaxis for patients undergoing ablative treatments and that the oral antiviral should be used for five days, starting one day before the procedure.
Close Menu